Genomic alterations may make cancer cells more dependent than normal cells on
mechanisms of proteostasis, including protein folding and degradation. This proposition is …

Proteasomes are large, multicatalytic protein complexes that cleave cellular proteins into
peptides. There are many distinct forms of proteasomes that differ in catalytically active …

Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …

Abstract Purpose: How exosomal RNAs released within the bone marrow microenvironment
affect proteasome inhibitors'(PI) sensitivity of multiple myeloma is currently unknown. This …

Despite the fundamental importance of proteasomal degradation in cells, little is known
about whether and how the 26S proteasome itself is regulated in coordination with various …

Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …

Proteasome is a multi-subunit protein degradation machine, which plays a key role in the
maintenance of protein homeostasis and, through degradation of regulatory proteins, in the …

The high failure rate of anticancer drug discovery and development has consumed billions
of dollars annually. While many explanations have been provided, I believe that …

The proteasome inhibitors carfilzomib (Cfz) and bortezomib (Btz) are used successfully to
treat multiple myeloma, but have not shown clinical efficacy in solid tumors. Here we show …

Proteasome inhibitors, such as bortezomib, are first-line therapy against multiple myeloma
(MM). Unfortunately, patients frequently become refractory to this treatment. The transcription …